BioVaxys Company
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma.
Technology:
Atrificial Vectors and Immune Cells
Industry:
Atrificial Vectors and Immune Cells
Headquarters:
New York, New York, United States
Founded Date:
2018-01-01
Employees Number:
1-10
Funding Status:
IPO
Total Funding:
3940555
Last Funding Date:
2022-08-04
Last Funding Type:
Post-IPO Equity
Register and Claim Ownership